# US 2020/0390759 A1 · Modulators of integrated stress response pathway

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390759 A1
- Document ID: US20200390759A1
- Status: Published application
- Kind: A1
- Application number: 16/899,521
- Filed: 2020-06-11
- Published: 2020-12-17
- Earliest claimed: 2019-06-12
- Assignees: Praxis Biotech LLC
- Applicants: Praxis Biotech LLC
- Inventors: Luz Marina DELGADO OYARZO; Gonzalo Andrés URETA DÍAZ; Brahmam PUJALA; Dayanand PANPATIL; Sebastian BERNALES
- Web page: https://patentgrep.com/patent/US20200390759A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A01N 43/42: condensed with carbocyclic rings
- A01N 43/60: 1,4-Diazines; Hydrogenated 1,4-diazines
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 215/06: having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07K 14/435: from animals; from humans
- C07K 14/4705: {stimulating, promoting or activating activity}
- C07K 2319/41: containing a Myc-tag
- C07K 2319/61: containing an enzyme fusion for detection (lacZ, luciferase)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates generally to therapeutic agents that may be useful as modulators of Integrated Stress Response (ISR) pathway.

## Claims

### Claim 1

A compound of formula (I):
or a salt thereof,
wherein:
X1 is N or CRX1;
X2 is N or CRX2;
when present, RX1 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, —C(O)OH, —C(O)O(C1-C6 alkyl), —C(O)O(C1-C6 haloalkyl), and halogen;
when present, RX2 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, —C(O)OH, —C(O)O(C1-C6 alkyl), —C(O)O(C1-C6 haloalkyl), and halogen;
R1, R2, R3, R4, R5, R6, R7, and R8, independently from each other, are selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, —C(O)OH, —C(O)O(C1-C6 alkyl), —C(O)O(C1-C6 haloalkyl), and halogen;
or, one of R1, R2, R3, R4, R5, R6, R7, and R8, and another one of R1, R2, R3, R4, R5, R6, R7, and R8, are taken together to form a C1-C6 alkylene moiety;
or, two geminal substituents selected from the group consisting of R1, R2, R3, R4, R5, R6, R7, and R8 are taken together to form an oxo group;
or, one of R1, R2, R3, R4, R5, R6, R7, and R8, and RX1, when present, are taken together to form a C1-C6 alkylene moiety;
R9 and R10, independently from each other, are selected from the group consisting of hydrogen, halogen, NO2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, —OH, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), —SH, —S(C1-C6 alkyl), —S(C1-C6 haloalkyl), —NH2, —NH(C1-C6 alkyl), —NH(C1-C6 haloalkyl), —N(C1-C6 alkyl)2, —N(C1-C6 haloalkyl)2, —NRB-aRB-b, —CN, —C(O)OH, —C(O)O(C1-C6 alkyl), —C(O)O(C1-C6 haloalkyl), —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)NH(C1-C6 haloalkyl), —C(O)N(C1-C6 alkyl)2, —C(O)N(C1-C6 haloalkyl)2, —C(O)NRB-aRB-b, —S(O)2OH, —S(O)2O(C1-C6 alkyl), —S(O)2O(C1-C6 haloalkyl), —S(O)2NH2, —S(O)2NH(C1-C6 alkyl), —S(O)2NH(C1-C6 haloalkyl), —S(O)2N(C1-C6 alkyl)2, —S(O)2N(C1-C6 haloalkyl)2, —S(O)2NRB-aRB-b, —OC(O)H, —OC(O)(C1-C6 alkyl), —OC(O)(C1-C6 haloalkyl), —N(H)C(O)H, —N(H)C(O)(C1-C6 alkyl), —N(H)C(O)(C1-C6 haloalkyl), —N(C1-C6 alkyl)C(O)H, —N(C1-C6 alkyl)C(O)(C1-C6 alkyl), —N(C1-C6 alkyl)C(O)(C1-C6 haloalkyl), —N(C1-C6 haloalkyl)C(O)H, —N(C1-C6 haloalkyl)C(O)(C1-C6 alkyl), —N(C1-C6 haloalkyl)C(O)(C1-C6 haloalkyl), —OS(O)2(C1-C6 alkyl), —OS(O)2(C1-C6 haloalkyl), —N(H)S(O)2(C1-C6 alkyl), —N(H)S(O)2(C1-C6 haloalkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 haloalkyl), —N(C1-C6 haloalkyl)S(O)2(C1-C6 alkyl), and —N(C1-C6 haloalkyl)S(O)2(C1-C6 haloalkyl);
wherein RB-a and RB-b are taken together with the nitrogen atom to which they are attached to form a 3-10 membered heterocycle;
R11 is selected from the group consisting of C3-C10 cycloalkyl optionally substituted with 1 to 17 R12 substituents and 3-10 membered heterocycloalkyl optionally substituted with 1 to 17 R12 substituents;
R12, independently at each occurrence, is selected from the group consisting of oxo, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, —OH, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), —SH, —S(C1-C6 alkyl), —S(C1-C6 haloalkyl), —NH2, —NH(C1-C6 alkyl), —NH(C1-C6 haloalkyl), —N(C1-C6 alkyl)2, —N(C1-C6 haloalkyl)2, —NRC-aRC-b, —CN, —C(O)OH, —C(O)O(C1-C6 alkyl), —C(O)O(C1-C6 haloalkyl), —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)NH(C1-C6 haloalkyl), —C(O)N(C1-C6 alkyl)2, —C(O)N(C1-C6 haloalkyl)2, —C(O)NRC-aRC-b, —S(O)2OH, —S(O)2O(C1-C6 alkyl), —S(O)2O(C1-C6 haloalkyl), —S(O)2NH2, —S(O)2NH(C1-C6 alkyl), —S(O)2NH(C1-C6 haloalkyl), —S(O)2N(C1-C6 alkyl)2, —S(O)2N(C1-C6 haloalkyl)2, —S(O)2NRC-aRC-b, —OC(O)H, —OC(O)(C1-C6 alkyl), —OC(O)(C1-C6 haloalkyl), —N(H)C(O)H, —N(H)C(O)(C1-C6 alkyl), —N(H)C(O)(C1-C6 haloalkyl), —N(C1-C6 alkyl)C(O)H, —N(C1-C6 alkyl)C(O)(C1-C6 alkyl), —N(C1-C6 alkyl)C(O)(C1-C6 haloalkyl), —N(C1-C6 haloalkyl)C(O)H, —N(C1-C6 haloalkyl)C(O)(C1-C6 alkyl), —N(C1-C6 haloalkyl)C(O)(C1-C6 haloalkyl), —OS(O)2(C1-C6 alkyl), —OS(O)2(C1-C6 haloalkyl), —N(H)S(O)2(C1-C6 alkyl), —N(H)S(O)2(C1-C6 haloalkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 haloalkyl), —N(C1-C6 haloalkyl)S(O)2(C1-C6 alkyl), and —N(C1-C6 haloalkyl)S(O)2(C1-C6 haloalkyl);
wherein RC-a and RC-b are taken together with the nitrogen atom to which they are attached to form a 3-10 membered heterocycle;
L is a linker selected from the group consisting of @-C1-C6 alkylene-#, @-NRN—(C1-C6 alkylene)-#, @-NRN—NRN—(C1-C6 alkylene)-#, @-CH2—NRN—(C1-C6 alkylene)-#, @-CH2—NRN—NRN—(C1-C6 alkylene)-#, @-NRN—(C1-C6 alkylene)-O-#, @—NRN—NRN—(C1-C6 alkylene)-O-#, @-CH2—NRN—(C1-C6 alkylene)-O-#, @-CH2—NRN—NRN—(C1-C6 alkylene)-O-#, and @-(C1-C6 alkylene)-O-#;
wherein @ represents the attachment point to X2 and # represents the attachment point to A;
the C1-C6 alkylene moiety of each of the @-C1-C6 alkylene-#, @-NRN—(C1-C6 alkylene)-#, @-NRN—NRN—(C1-C6 alkylene)-#, @-CH2—NRN—(C1-C6 alkylene)-#, @-CH2—NRN—NRN—(C1-C6 alkylene)-#, @-NRN—(C1-C6 alkylene)-O-#, @-NRN—NRN—(C1-C6 alkylene)-O-#, @-CH2—NRN—(C1-C6 alkylene)-O-#, @-CH2—NRN—NRN—(C1-C6 alkylene)-O-#, and @-(C1-C6 alkylene)-O-# is optionally substituted with 1 to 12 R13;
RN, independently at each occurrence, is selected from the group consisting of hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl,
R13, independently at each occurrence, is selected from the group consisting of oxo, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, —OH, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), —SH, —S(C1-C6 alkyl), —S(C1-C6 haloalkyl), —NH2, —NH(C1-C6 alkyl), —NH(C1-C6 haloalkyl), —N(C1-C6 alkyl)2, —N(C1-C6 haloalkyl)2, —NRL-aRL-b, —CN, —C(O)OH, —C(O)O(C1-C6 alkyl), —C(O)O(C1-C6 haloalkyl), —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)NH(C1-C6 haloalkyl), —C(O)N(C1-C6 alkyl)2, —C(O)N(C1-C6 haloalkyl)2, —C(O)NRL-aRL-b, —S(O)2OH, —S(O)20(C1-C6 alkyl), —S(O)2O(C1-C6 haloalkyl), —S(O)2NH2, —S(O)2NH(C1-C6 alkyl), —S(O)2NH(C1-C6 haloalkyl), —S(O)2N(C1-C6 alkyl)2, —S(O)2N(C1-C6 haloalkyl)2, —S(O)2NRL-aRL-b, —OC(O)H, —OC(O)(C1-C6 alkyl), —OC(O)(C1-C6 haloalkyl), —N(H)C(O)H, —N(H)C(O)(C1-C6 alkyl), —N(H)C(O)(C1-C6 haloalkyl), —N(C1-C6 alkyl)C(O)H, —N(C1-C6 alkyl)C(O)(C1-C6 alkyl), —N(C1-C6 alkyl)C(O)(C1-C6 haloalkyl), —N(C1-C6 haloalkyl)C(O)H, —N(C1-C6 haloalkyl)C(O)(C1-C6 alkyl), —N(C1-C6 haloalkyl)C(O)(C1-C6 haloalkyl), —OS(O)2(C1-C6 alkyl), —OS(O)2(C1-C6 haloalkyl), —N(H)S(O)2(C1-C6 alkyl), —N(H)S(O)2(C1-C6 haloalkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 haloalkyl), —N(C1-C6 haloalkyl)S(O)2(C1-C6 alkyl), and —N(C1-C6 haloalkyl)S(O)2(C1-C6 haloalkyl);
wherein RL-a and RL-b are taken together with the nitrogen atom to which they are attached to form a 3-10 membered heterocycle;
A is selected from the group consisting of:
a substituent of formula (A-1)
W2 is selected from the group consisting of —C(RW2-1RW2-2)—, —N(RW2-2)—, —C(RW2-1RW2-1)N(RW2-2)—, —N(RW2-1)C(RW2-1RW2-2)—, —C(RW2-1)═N—, —N═C(RW2-1)—, —O—, —C(RW2-1RW2-1)O—, —OC(RW2-1RW2-2)+, —S—, —C(RW2-1RW2-1)S—, —SC(RW2-1RW2-2)—, —C(RW2-1RW2-1)C(RW2-1RW2-2)—, and —CRW2-1═CRW2-1—,
wherein RW2-1 is H or RA, and RW2-2 is H or RA;
W3 is selected from the group consisting of —C(RW3-1RW3-2)—, —N(RW3-2)—, —C(RW3-1RW3-1)N(R3-2)—, —N(RW3-1)C(RW3-1RW3-2)—, —C(RW3-1)═N—, —N═C(RW3-1)—, —O—, —C(RW3-1RW3-1)O—, —OC(RW3-1R3-2)—, —S—, —C(RW3-1RW3-1)S—, —SC(RW3-1RW3-2)—, —C(RW3-1RW3-1)C(RW3-1RW3-2)—, and —CRW3-1═CRW3-1—,
wherein RW3-1 is H or RA, and RW3-2 is H or RA;
W4, independently at each occurrence, is CRW4 or N, wherein RW4 is H or RA;
RW1 is hydrogen or RA, or RW1 and RW2-2 are taken together to form a double bond between the carbon atom bearing RW1 and the atom bearing RW2-2, or RW1 and RW3-2 are taken together to form a double bond between the carbon atom bearing RW1 and the atom bearing RW3-2;
C6-C14 aryl optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, or 9 RA substituents; and
5-14 membered heteroaryl optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, or 9 RA substituents;
RA, independently at each occurrence, is selected from the group consisting of halogen, NO2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, —OH, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), —SH, —S(C1-C6 alkyl), —S(C1-C6 haloalkyl), —NH2, —NH(C1-C6 alkyl), —NH(C1-C6 haloalkyl), —N(C1-C6 alkyl)2, —N(C1-C6 haloalkyl)2, —NRA-aRA-b, —CN, —C(O)OH, —C(O)O(C1-C6 alkyl), —C(O)O(C1-C6 haloalkyl), —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)NH(C1-C6 haloalkyl), —C(O)N(C1-C6 alkyl)2, —C(O)N(C1-C6 haloalkyl)2, —C(O)NRA-aRA-b, —S(O)2OH, —S(O)2O(C1-C6 alkyl), —S(O)2O(C1-C6 haloalkyl), —S(O)2NH2, —S(O)2NH(C1-C6 alkyl), —S(O)2NH(C1-C6 haloalkyl), —S(O)2N(C1-C6 alkyl)2, —S(O)2N(C1-C6 haloalkyl)2, —S(O)2NRA-aRA-b, —OC(O)H, —OC(O)(C1-C6 alkyl), —OC(O)(C1-C6 haloalkyl), —N(H)C(O)H, —N(H)C(O)(C1-C6 alkyl), —N(H)C(O)(C1-C6 haloalkyl), —N(C1-C6 alkyl)C(O)H, —N(C1-C6 alkyl)C(O)(C1-C6 alkyl), —N(C1-C6 alkyl)C(O)(C1-C6 haloalkyl), —N(C1-C6 haloalkyl)C(O)H, —N(C1-C6 haloalkyl)C(O)(C1-C6 alkyl), —N(C1-C6 haloalkyl)C(O)(C1-C6 haloalkyl), —OS(O)2(C1-C6 alkyl), —OS(O)2(C1-C6 haloalkyl), —N(H)S(O)2(C1-C6 alkyl), —N(H)S(O)2(C1-C6 haloalkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 haloalkyl), —N(C1-C6 haloalkyl)S(O)2(C1-C6 alkyl), and —N(C1-C6 haloalkyl)S(O)2(C1-C6 haloalkyl);
wherein RA-a and RA-b are taken together with the nitrogen atom to which they are attached to form a 3-10 membered heterocycle;
provided that when X2 is N, then L is a linker selected from the group consisting of @-C1-C6 alkylene-#, @-NRN—(C1-C6 alkylene)-#, @-NRN—(C1-C6 alkylene)-O-#, and @-(C1-C6 alkylene)-O-#.

### Claim 2 (depends on 1)

The compound of claim 1, or a salt thereof, wherein the compound of formula (I) is a compound of formula (II):
or a salt thereof,
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X1, L, and A are as defined in claim 1.

### Claim 3 (depends on 1)

The compound of claim 1, or a salt thereof, wherein the compound of formula (I) is a compound of formula (III):
or a salt thereof,
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, CRX1, L, and A are as defined in claim 1.

### Claim 4 (depends on 1)

The compound of claim 1, or a salt thereof, wherein the compound of formula (I) is a compound of formula (IV):
or a salt thereof,
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, L, and A are as defined in claim 1.

### Claim 5 (depends on 1)

The compound of claim 1, or a salt thereof, wherein the compound of formula (I) is a compound of formula (V):
or a salt thereof,
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, L, and A are as defined in claim 1.

### Claim 6 (depends on 1)

The compound of claim 1, or a salt thereof, wherein the compound of formula (I) is a compound of formula (VI):
or a salt thereof,
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, L, and A are as defined in claim 1.

### Claim 7 (depends on 1)

The compound of claim 1, or a salt thereof, wherein the compound of formula (I) is a compound of formula (VII):
or a salt thereof,
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, CRX2, L, and A are as defined in claim 1.

### Claim 8 (depends on 1)

The compound of claim 1, or a salt thereof, wherein the compound of formula (I) is a compound of formula (VIII):
or a salt thereof,
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, L, and A are as defined in claim 1.

### Claim 9 (depends on 1)

The compound of claim 1, or a salt thereof, wherein L is

### Claim 10 (depends on 9)

The compound of claim 9, or a salt thereof, wherein L is

### Claim 11 (depends on 9)

The compound of claim 9, or a salt thereof, wherein L is

### Claim 12 (depends on 1)

The compound of claim 1, or a salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and R8 are each hydrogen.

### Claim 13 (depends on 1)

The compound of claim 1, or a salt thereof, wherein R9 and R10 are each halogen.

### Claim 14 (depends on 1)

The compound of claim 1, or a salt thereof, wherein R9 is chloro and R10 is fluoro.

### Claim 15 (depends on 1)

The compound of claim 1, or a salt thereof, wherein A is
wherein * represents that attachment point to the remainder of the molecule.

### Claim 16

A compound selected from the group consisting of:
or a salt thereof.

### Claim 17

A compound selected from the group consisting of:
or a salt thereof.

### Claim 18

A compound selected from the group consisting of a compound of Table 1, or a salt thereof.

### Claim 19

A pharmaceutical composition comprising a compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A method for enhancing protein synthesis in a living organism, comprising administering to the living organism an effective amount of a compound of claim 1, or a salt thereof.

### Claim 21 (depends on 1)

A method for accelerating growth of a plant, comprising administering to the plant an effective amount of a compound of claim 1, or a salt thereof.

### Claim 22 (depends on 1)

A method for improving protein yield or quality in a plant, comprising administering to the plant an effective amount of a compound of claim 1, or a salt thereof.

### Claim 23 (depends on 22)

The method of claim 22, wherein the plant is selected from soybean, sunflower, grain legume, rice, wheat germ, maize, tobacco, a cereal, and a lupin crop.

### Claim 24 (depends on 1)

A method of treating a disease or disorder mediated by an integrated stress response (ISR) pathway in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein the compound, the pharmaceutically acceptable salt, or the pharmaceutical composition is administered in combination with a therapeutically effective amount of one or more additional anti-cancer agents.

### Claim 26 (depends on 24)

The method of claim 24, wherein the disease or disorder is mediated by phosphorylation of eIF2α and/or the guanine nucleotide exchange factor (GEF) activity of eIF2B.

### Claim 27 (depends on 24)

The method of claim 24, wherein the disease or disorder is mediated by a decrease in protein synthesis.

### Claim 28 (depends on 24)

The method of claim 24, wherein the disease or disorder is mediated by the expression of ATF4, CHOP or BACE-1.

### Claim 29 (depends on 24)

The method of claim 24, wherein the disease or disorder is a neurodegenerative disease, an inflammatory disease, an autoimmune disease, a metabolic syndrome, a cancer, a vascular disease, an ocular disease, a musculoskeletal disease, or a genetic disorder.

### Claim 30 (depends on 29)

The method of claim 29, wherein the disease is vanishing white matter disease, childhood ataxia with CNS hypomyelination, intellectual disability syndrome, Alzheimer's disease, prion disease, Creutzfeldt-Jakob disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) disease, cognitive impairment, frontotemporal dementia (FTD), traumatic brain injury, postoperative cognitive dysfunction (PCD), neuro-otological syndromes, hearing loss, Huntington's disease, stroke, chronic traumatic encephalopathy, spinal cord injury, dementias or cognitive impairment, arthritis, psoriatic arthritis, psoriasis, juvenile idiopathic arthritis, asthma, allergic asthma, bronchial asthma, tuberculosis, chronic airway disorder, cystic fibrosis, glomerulonephritis, membranous nephropathy, sarcoidosis, vasculitis, ichthyosis, transplant rejection, interstitial cystitis, atopic dermatitis or inflammatory bowel disease, Crohn's disease, ulcerative colitis, celiac disease, systemic lupus erythematosus, type 1 diabetes, multiple sclerosis, rheumatoid arthritis, acute pancreatitis, chronic pancreatitis, alcoholic liver steatosis, obesity, glucose intolerance, insulin resistance, hyperglycemia, fatty liver, dyslipidemia, hyperlipidemia, type 2 diabetes, pancreatic cancer, breast cancer, kidney cancer, bladder cancer, prostate cancer, testicular cancer, urothelial cancer, endometrial cancer, ovarian cancer, cervical cancer, renal cancer, esophageal cancer, gastrointestinal stromal tumor (GIST), multiple myeloma, cancer of secretory cells, thyroid cancer, gastrointestinal carcinoma, chronic myeloid leukemia, hepatocellular carcinoma, colon cancer, melanoma, malignant glioma, glioblastoma, glioblastoma multiforme, astrocytoma, dysplastic gangliocytoma of the cerebellum, Ewing's sarcoma, rhabdomyosarcoma, ependymoma, medulloblastoma, ductal adenocarcinoma, adenosquamous carcinoma, nephroblastoma, acinar cell carcinoma, lung cancer, non-Hodgkin's lymphoma, Burkitt's lymphoma, chronic lymphocytic leukemia, monoclonal gammopathy of undetermined significance (MGUS), plasmocytoma, lymphoplasmacytic lymphoma, acute lymphoblastic leukemia, Pelizaeus-Merzbacher disease, atherosclerosis, abdominal aortic aneurism, carotid artery disease, deep vein thrombosis, Buerger's disease, chronic venous hypertension, vascular calcification, telangiectasia or lymphoedema, glaucoma, age-related macular degeneration, inflammatory retinal disease, retinal vascular disease, diabetic retinopathy, uveitis, rosacea, Sjogren's syndrome or neovascularization in proliferative retinopathy, hyperhomocysteinemia, skeletal muscle atrophy, myopathy, muscular dystrophy, muscular wasting, sarcopenia, Duchenne muscular dystrophy (DMD), Becker's disease, myotonic dystrophy, X-linked dilated cardiomyopathy, spinal muscular atrophy (SMA), Down syndrome, MEHMO syndrome, metaphyseal chondrodysplasia, Schmid type (MCDS), depression, or social behavior impairment.

### Claim 31 (depends on 1)

A method of producing a protein, comprising contacting a eukaryotic cell comprising a nucleic acid encoding the protein with the compound or salt of claim 1.

### Claim 32 (depends on 31)

The method of claim 31, comprising culturing the cell in an in vitro culture medium comprising the compound or salt.

### Claim 33 (depends on 1)

A method of culturing a eukaryotic cell comprising a nucleic acid encoding a protein, comprising contacting the eukaryotic cell with an in vitro culture medium comprising a compound or salt of claim 1.

### Claim 34 (depends on 31)

The method of claim 31, wherein the nucleic acid encoding the protein is a recombinant nucleic acid.

### Claim 35 (depends on 31)

The method of claim 31, wherein the cell is a human embryonic kidney (HEK) cell or a Chinese hamster ovary (CHO) cell.

### Claim 36 (depends on 1)

A method of producing a protein, comprising contacting a cell-free protein synthesis (CFPS) system comprising eukaryotic initiation factor 2 (eIF2) and a nucleic acid encoding a protein with the compound or salt of claim 1.

### Claim 37 (depends on 31)

The method of claim 31, wherein the protein is an antibody or a fragment thereof.

### Claim 38 (depends on 31)

The method of claim 31, comprising purifying the protein.

### Claim 39 (depends on 1)

An in vitro cell culture medium, comprising the compound or salt of claim 1 and nutrients for cellular growth.

### Claim 40 (depends on 39)

The cell culture medium of claim 39, comprising a eukaryotic cell comprising a nucleic acid encoding a protein.

### Claim 41 (depends on 39)

The cell culture medium of claim 39, further comprising a compound for inducing protein expression.

### Claim 42 (depends on 39)

The cell culture medium of claim 39, wherein the nucleic acid encoding the protein is a recombinant nucleic acid.

### Claim 43 (depends on 39)

The cell culture medium of claim 39, wherein the protein is an antibody or a fragment thereof.

### Claim 44 (depends on 39)

The cell culture medium of claim 39, wherein the eukaryotic cell is a human embryonic kidney (HEK) cell or a Chinese hamster ovary (CHO) cell.

### Claim 45 (depends on 1)

A cell-free protein synthesis (CFPS) system comprising eukaryotic initiation factor 2 (eIF2) and a nucleic acid encoding a protein with the compound or salt of claim 1.

### Claim 46 (depends on 45)

The CFPS system of claim 45, comprising a eukaryotic cell extract comprising eIF2.

### Claim 47 (depends on 45)

The CFPS system of claim 45, further comprising eIF2B.

### Claim 48 (depends on 45)

The CFPS system of claim 45, wherein the protein is an antibody or a fragment thereof.
